Molecular Medicine

, Volume 13, Issue 9–10, pp 542–550 | Cite as

Differences in Extracellular Matrix Production and Basic Fibroblast Growth Factor Response in Skin Fibroblasts from Sporadic and Familial Alzheimer’s Disease

  • Catia Bellucci
  • Cinzia Lilli
  • Tiziano Baroni
  • Lucilla Parnetti
  • Sandro Sorbi
  • Carla Emiliani
  • Eleonora Lumare
  • Paolo Calabresi
  • Stefania Balloni
  • Maria Bodo
Research Article


Extracellular matrix (ECM) molecules and growth factors, such as fibroblast growth factor (FGF), play a crucial role in Alzheimer’s disease (AD). The purpose of this investigation was to determine whether phenotypic alterations in ECM production are present in non-neuronal AD cells associated with different FGF expression and response. Synthesis of glycosaminoglycans (GAG) and collagen were measured in skin fibroblasts from patients with familial, sporadic AD (FAD and SAD respectively), and from age-matched controls by radiolabeled precursors. Proteoglycans (PG), metalloprotease (MMP)-1, and FGF gene expressions were measured by reverse transcription-polymerase chain reaction. The results showed different ECM neosynthesis and mRNA levels in the two AD fibroblast populations. FAD accumulated more collagen and secreted less GAG than SAD. Biglycan PG was upregulated in FAD while betaglycan, syndecan, and decorin were markedly downregulated in SAD fibroblasts. We found a significant decrease of MMP1, more marked in FAD than in SAD fibroblasts. Constitutive FGF expression was greatly reduced in both pathological conditions (SAD > FAD). Moreover, an inverse high affinity/low affinity FGF receptor ratio between SAD and FAD fibroblasts was observed. FGF treatment differently modulated ECM molecule production and gene expression in the two cell populations. These observations in association with the changes in FGF gene expression and in the FGF receptor number, suggest that cellular mechanisms downstream from FGF receptor binding are involved in the two different forms of AD.



Supported by fundings from the University of Perugia, by the Italian Ministry of Instruction, University and Research (Grant 2005051707–005 and 2005062887–004) and by the Cassa di Risparmio of Florence (Grant 2003.1764).


  1. 1.
    Smith MA. (1998) Alzheimer disease. Int. Rev. Neurobiol. 42:1–54.CrossRefGoogle Scholar
  2. 2.
    Hardy J. (1997) Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci. 20:154–9.CrossRefGoogle Scholar
  3. 3.
    Castillo GM, Ngo C, Cummings J, Wight TN, Snow AD. (1997) Perlecan binds to the β-amyloid proteins (Aβ) of Alzheimer’s disease, accelerates Aβ fibril formation, and maintains Aβ fibril stability. J. Neurochem. 69:2452–65.CrossRefGoogle Scholar
  4. 4.
    Bruckner G, Hausen D, Harting W, Drlicek M, Arendt T, Brauer K. (1999) Cortical areas abundant in extracellular matrix chondroitin sulphate proteoglycans are less affected by cytoskeletal changes in Alzheimer’s disease. Neuroscience 92:791–805.CrossRefGoogle Scholar
  5. 5.
    Gerst JL et al. (2000) Altered cell-matrix associated ADAM proteins in Alzheimer disease. J. Neurosc. Res. 59:680–4.CrossRefGoogle Scholar
  6. 6.
    Ge YW, Lahiri DK. (2002) Regulation of promoter activity of the APP gene by cytokines and growth factors: implications in Alzheimer’s disease. Ann. N. Y. Acad. Sci. 973:463–7.CrossRefGoogle Scholar
  7. 7.
    Gilad GM, Kagan HM, Gilad VH. (2005) Evidence for increased lysyl oxidase, the extracellular matrix-forming enzyme, in Alzheimer’s disease brain. Neurosci. Lett. 376:210–4.CrossRefGoogle Scholar
  8. 8.
    Monning U, Sandbrink R, Weidemann A, Banati RB, Masters CL, Beyreuther K. (1995) Extracellular matrix influences the biogenesis of amyloid precursor protein in microglial cells. J. Biol. Chem. 270:7104–10.CrossRefGoogle Scholar
  9. 9.
    Berzin TM et al. (2000) Agrin and microvascular damage in Alzheimer’s disease. Neurobiol. Aging. 21:349–55.CrossRefGoogle Scholar
  10. 10.
    Van Horssen J et al. (2002) Collagen XVIII: a novel heparan sulfate proteoglycan associated with vascular amyloid depositions and senile plaques in Alzheimer’s disease brains. Brain Pathol. 12:456–62.CrossRefGoogle Scholar
  11. 11.
    Snow AD, Sekiguchi RT, Nochlin D, Kalaria RN, Kimata K. (1994) Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer’s disease brain. Am. J. Pathol. 144:337–47.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Snow AD et al. (1995) Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin and versican) to the beta amyloid protein of Alzheimer’s disease. Arch. Biochem. Biophys. 320:84–95.CrossRefGoogle Scholar
  13. 13.
    Snow AD, Wight TN. (1989) Proteoglycans in the pathogenesis of Alzheimer’s disease and other amyloidoses. Neurobiol. Aging. 10:481–97.CrossRefGoogle Scholar
  14. 14.
    DeWitt DA, Silver J, Canning DR, Perry G. (1993) Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer’s disease. Exp. Neurol. 121:149–52.CrossRefGoogle Scholar
  15. 15.
    Snow AD, Castillo GM. (1997) Specific proteoglycans as potential causative agents and relevant targets for therapeutic intervention in Alzheimer’s disease and other amyloidoses. Amyloid: Int. J. Exp. Clin. Invest. 4:135–41.CrossRefGoogle Scholar
  16. 16.
    Mattson MP et al. (1997) Cellular signaling roles of TGFβ, TNFα, and βAPP in brain injury responses and Alzheimer’s disease. Brain Res. Rev. 23:47–61CrossRefGoogle Scholar
  17. 17.
    Griffin WS et al. (1998) Glial-neuronal interactions in Alzheimer’s disease: the potential role of a “cytokine cycle” in disease progression. Brain Pathol. 8:65–72.CrossRefGoogle Scholar
  18. 18.
    Satoh J, Kuroda Y. (2000) Amyloid precursor proteinβ-secretase (BACE) mRNA expression in human neural cell lines following induction of neuronal differentiation and exposure to cytokines and growth factors. Neuropathology. 20: 289–96.CrossRefGoogle Scholar
  19. 19.
    Eckenstein FP. (1994) Fibroblast growth factors in the nervous system. J. Neurobiol. 25:1467–80.CrossRefGoogle Scholar
  20. 20.
    Eckenstein FP, Andersson C, Kuzis K, Woodward WR. (1994) Distribution of acidic and basic fibroblast growth factors in the mature, injured and developing rat nervous system. Prog. Brain Res. 103:55–64.CrossRefGoogle Scholar
  21. 21.
    Reier PJ, Houle J. (1988). The glial scar: its bearing on axonal elongation and transplantation approaches to CNS repair. Adv. Neurol. 47:87–138.PubMedGoogle Scholar
  22. 22.
    Ecklancher F, Kehrli P, Labourdette G, Sensenbrenner M. (1996) Basic fibroblast growth factor (bFGF) injection activates the glial reaction in the injured adult rat brain. Brain Res. 737:201–14.CrossRefGoogle Scholar
  23. 23.
    Kuzis K, Reed S, Cherry NJ, Woodward WR, Eckenstein FP. (1995) Developmental time course of acidic and basic fibroblast growth factors’ expression in distinct cellular populations of the rat central nervous system. J. Comp. Neurol. 358: 142–53.CrossRefGoogle Scholar
  24. 24.
    Johnson DE, Williams LT. (1993) Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res. 60:1–41.PubMedGoogle Scholar
  25. 25.
    Stopa EG et al. (1990) Basic fibroblast growth factor in Alzheimer’s disease. Biochem. Biophys. Res. Commun. 171:690–6.CrossRefGoogle Scholar
  26. 26.
    Lahiri DK, Nall C. (1995) Promoter activity of the gene encoding the beta-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and interleukin-1. Brain Res. Mol. Brain Res. 32:233–40.CrossRefGoogle Scholar
  27. 27.
    Perry G et al. (1991) Association of heparan sulfate proteoglycan with the neurofibrillary tangles of Alzheimer’s disease. J. Neurosci. 11:3679–83.CrossRefGoogle Scholar
  28. 28.
    Matsumoto A, Fujiwara Y. (1993) Aberrant proteolysis of the β-amyloid precursor protein in familial Alzheimer’s disease lympho-blastoid cells. Eur. J. Biochem. 217:21–7.CrossRefGoogle Scholar
  29. 29.
    Fukumoto H, Tomita T, Matsunaga H, Ishibashi Y, Saido TC, Iwatsubo T. (1999) Primary cultures of neuronal and non-neuronal rat brain cells secrete similar proportions of amyloid beta peptides ending at A beta40 and A beta42. Neuroreport. 10:2965–9.CrossRefGoogle Scholar
  30. 30.
    Horiguchi Y, Fine JD, Leigh IM, Yoshiki T, Ueda M, Imamura S. (1992) Lamina densa malformation involved in histogenesis of primary localized cutaneous amyloidosis. J. Invest. Dermatol. 99:12–8.CrossRefGoogle Scholar
  31. 31.
    Schultz RT, Pitha J. (1985) Relation of the hepatic and splenic microcirculations to the development of lesions in experimental amyloidosis. Am. J. Pathol. 119:127–37.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Young ID, Willmer JP, Kisilevsky RI. (1989) The ultrastructural localization of sulfated proteoglycans is identical in the amyloids of Alzheimer’s disease and AA, AL, senile cardiac and medullary carcinoma-associated amyloidosis. Acta Neuropathol. 78:202–9.CrossRefGoogle Scholar
  33. 33.
    Czech C, Tremp G, Pradier L. (2000) Presenilins and Alzheimer’s disease: biological functions and pathogenic mechanisms. Prog. Neurobiol. 60:363–84.CrossRefGoogle Scholar
  34. 34.
    Hardy J, Selkoe DJ. (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 297:353–6.CrossRefGoogle Scholar
  35. 35.
    De Strooper B. (2003) Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron. 38:9–12.CrossRefGoogle Scholar
  36. 36.
    Thinakaran G, Parent AT. (2004) Identification of the role of presenilins beyond Alzheimer’s disease. Pharmacol. Res. 50:411–8.CrossRefGoogle Scholar
  37. 37.
    Bertram L et al. (2005) Family-based association between Alzheimer’s disease and variants in UBQLN1. N. Engl. J. Med. 352:884–94.CrossRefGoogle Scholar
  38. 38.
    Li D et al. (2006) Mutations of presenilin genes in dilated cardiomyopathy and heart failure. Am. J. Hum. Genet. 79:1030–9.CrossRefGoogle Scholar
  39. 39.
    Uberti D et al. (2002) Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer’s disease patients. J. Cell Sci. 115: 3131–8.PubMedGoogle Scholar
  40. 40.
    Trippi F et al. (2001) Spontaneous and induced chromosome damage in somatic cells of sporadic and familial Alzheimer’s disease patients. Mutagenesis. 16:323–7.CrossRefGoogle Scholar
  41. 41.
    Emiliani C et al. (2003) Up-regulation of glycohydrolases in Alzheimer’s disease fibroblasts correlates with Ras activation. J. Biol. Chem. 278:38453–60.CrossRefGoogle Scholar
  42. 42.
    Cecchi C et al. (2007) Increased susceptibility to amyloid toxicity in familial Alzheimer’s fibroblasts. Neurobiol. Aging. 28:863–76.CrossRefGoogle Scholar
  43. 43.
    Conrad GW, Hamilton C, Haynes E. (1977) Differences in glycosaminoglycans synthesized by fibroblast-like cells from chick cornea, heart, and skin. J. Biol. Chem. 252:6861–70.PubMedGoogle Scholar
  44. 44.
    Webster DF, Harvey W. (1979) A quantitative assay for collagen synthesis in microwell fibroblasts cultures. Anal. Biochem. 96:220–4.CrossRefGoogle Scholar
  45. 45.
    Moscatelli D. (1987) High and low affinity binding sites for basic fibroblast growth factor on cultured cells: absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. J. Cell Physiol. 131:123–30.CrossRefGoogle Scholar
  46. 46.
    Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. (1991) Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to his high affinity receptor. Cell. 64:841–8.CrossRefGoogle Scholar
  47. 47.
    Scatchard G. (1949) The attractions of proteins for small molecules and ions. Ann. NY Acad. Science. 51:660–72.CrossRefGoogle Scholar
  48. 48.
    Magnus JH, Stenstad T. (1997) Proteoglycans and the extracellular matrix in amyloidosis. Amyloid: Int. J. Exp. Clin. Invest. 4:121–34.CrossRefGoogle Scholar
  49. 49.
    Deininger MH, Fimmen BA, Thal DR, Schluesener HJ, Meyermann R. (2002) Aberrant neuronal and paracellular deposition of endostatin in brains of patients with Alzheimer’s disease. J. Neuroscience. 22:10621–6.CrossRefGoogle Scholar
  50. 50.
    Narindrasorasak S, Lowery DE, Altman RA, Gonzales DP, Greenberg B, Kisilevsky R. (1992) Characterization of high affinity binding between laminin and Alzheimer’s disease amyloid precursor proteins. Lab. Invest. 67:643–52.PubMedGoogle Scholar
  51. 51.
    Matsumoto A, Enomoto T, Fujiwara Y, Baba H, Matsumoto R. (1996) Enhanced aggregation of beta-amyloid-containing peptides by extracellular matrix and their degradation by the 68 kDa serine protease prepared from human brain. Neurosc. Lett. 220:159–62CrossRefGoogle Scholar
  52. 52.
    Cecchi C et al. (1999) Gluthatione level is altered in lymphoblasts from patients with familial Alzheimer’s disease. Neurosci. Lett. 275:152–4.CrossRefGoogle Scholar
  53. 53.
    Bagnoli S et al. (2002) Cathepsin D polymorphism in Italian sporadic and familial Alzheimer’s disease. Neurosci. Lett. 328:273–6.CrossRefGoogle Scholar
  54. 54.
    Fillit H, Leveugle B. (1995) Disorders of the extracellular matrix and the pathogenesis of senile dementia of the Alzheimer’s type. Lab. Invest. 72:249–53.PubMedGoogle Scholar
  55. 55.
    Kahari VM, Larjava H, Uitto J. (1991) Differential regulation of extracellular matrix proteoglycan (PG) gene expression. Transforming growth factor-beta 1 up-regulates biglycan (PGI), and versican (large fibroblast PG) but down-regulates decorin (PGII) mRNA levels in human fibroblasts in culture. J. Biol. Chem. 266:10608–15.PubMedGoogle Scholar
  56. 56.
    Stichel CC, Kappler J, Junghans U, Koops A, Kresse H, Muller HW. (1995) Differential expression of the small chondroitin/dermatan sulfate proteoglycans decorin and biglycan after injury of the adult rat brain. Brain Res. 704:263–74.CrossRefGoogle Scholar
  57. 57.
    Cosgaya JM, Latasa MJ, Pascual A. (1996) Nerve growth factor and ras regulate beta-amyloid precursor protein gene expression in PC12 cells. J. Neurochem. 67:98–104.CrossRefGoogle Scholar
  58. 58.
    Abe K, Saito H. (2001) Effects of basic fibroblast growth factor on central nervous system functions. Pharmacol. Res. 43:307–12.CrossRefGoogle Scholar
  59. 59.
    Furukawa K, Fu W, Li Y, Witke W, Kwiatkowski DJ, Mattson MP. (1997) The actin-severing protein gelsolin modulates calcium channel and NMDA receptor activities and vulnerability to excitotoxicity in hippocampal neurons. J. Neurosci. 17: 8178–86.CrossRefGoogle Scholar
  60. 60.
    Thorns V, Masliah E, (1999) Evidence for neuroprotective effects of acidic fibroblast growth factor in Alzheimer disease. J. Neuropathol. Exp. Neurol. 58:296–306.CrossRefGoogle Scholar
  61. 61.
    Masliah E et al. (1997) Amyloid precursor proteins protect neurons of transgenic mice against acute and chronic excitotoxic injuries in vivo. Neuroscience. 78:135–46.CrossRefGoogle Scholar
  62. 62.
    Guo Q et al. (1999) Neurotrophic factors (activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)) interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc. Natl. Acad. Sci. U. S. A. 96: 4125–30.CrossRefGoogle Scholar
  63. 63.
    Tsukamoto E, Hashimoto Y, Kanekura K, Niikura T, Aiso S, Nishimoto I. (2003) Characterization of the toxic mechanism triggered by Alzheimer’s amyloid-beta peptides via p75 neurotrophin receptor in neuronal hybrid cells. J. Neurosci. Res. 73:627–36.CrossRefGoogle Scholar
  64. 64.
    Mosconi L et al. (2003) Brain metabolic differences between sporadic and familial Alzheimer’s disease. Neurology. 61:1138–40.CrossRefGoogle Scholar
  65. 65.
    Flint N, Cove FL, Evans GS. (1994) Heparin stimulates the proliferation of intestinal epithelial cells in primary culture. J. Cell Sci. 107:401–11.PubMedGoogle Scholar
  66. 66.
    Klagsbrun M, Baird A. (1991) Adual receptor system is required for basic fibroblast growth factor activity. Cell. 67:229–31.CrossRefGoogle Scholar
  67. 67.
    Aviezer D et al. (1994) Differential structural requirements of heparin and heparin sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor. J. Biol. Chem. 269:114–21.PubMedGoogle Scholar
  68. 68.
    Leveugle B et al. (1997) Heparin promotes betasecretase cleavage of the Alzheimer’s amyloid precursorprotein. Neurochem. Int. 30:543–8.CrossRefGoogle Scholar
  69. 69.
    Leveugle B et al. (1998) Heparin oligosaccharides that pass the blood-brain barrier inhibit β-amyloid precursor protein secretion and heparin binding to β-amyloid peptide. J. Neurochem. 70:736–44.CrossRefGoogle Scholar

Copyright information

© Feinstein Institute for Medical Research 2007

Authors and Affiliations

  • Catia Bellucci
    • 1
  • Cinzia Lilli
    • 1
  • Tiziano Baroni
    • 1
  • Lucilla Parnetti
    • 2
  • Sandro Sorbi
    • 3
  • Carla Emiliani
    • 1
  • Eleonora Lumare
    • 4
  • Paolo Calabresi
    • 2
  • Stefania Balloni
    • 1
  • Maria Bodo
    • 2
  1. 1.Department of Experimental Medicine and Biochemical SciencesUniversity of PerugiaPerugiaItaly
  2. 2.Department of Specialistic Medicine and Public Health, Neuroscience Clinical sectionUniversity of PerugiaPerugiaItaly
  3. 3.Department of Neurologic and Psychiatric SciencesUniversity of FirenzeFirenzeItaly
  4. 4.Forensic Medicine InstituteUniversity of PerugiaPerugiaItaly

Personalised recommendations